2016. pii: S0140 - 6736(16)32517 -X. doi: 10.1016/S0140 -6736(16)32517 -X. 69. Rizvi N, Brahmer J, Ou SH et al. Safety and clinical activityof MEDI4736, an anti - programmed cell death -ligand (PD -L1) antibody in patients with non -small -cell lung cancer. J Clin Oncol 2015; 33 (suppl; abstr 8032) 70. Rizvi NA, Garon E, Leighl N et al. Optimizing PD -L1 as biomarker of response with pembrolizumab as first -line therapy for PD -L1 positive metastatic non -small cell lung cancer: updated data from KEYNOTE -001. J Clin Oncol 2015; 33 (suppl; abstr 8026) 71.